| 0.917 -0.003 (-0.33%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.15 | 1-year : | 1.35 |
| Resists | First : | 0.99 | Second : | 1.15 |
| Pivot price | 0.84  |
|||
| Supports | First : | 0.83 | Second : | 0.73 |
| MAs | MA(5) : | 0.87 |
MA(20) : | 0.82 |
| MA(100) : | 1.07  |
MA(250) : | 1.43 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 60.8 |
D(3) : | 49.3 |
| RSI | RSI(14): 60.7 |
|||
| 52-week | High : | 2.48 | Low : | 0.63 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LGVN ] has closed below upper band by 9.7%. Bollinger Bands are 53.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 41 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.94 - 0.95 | 0.95 - 0.95 |
| Low: | 0.89 - 0.89 | 0.89 - 0.9 |
| Close: | 0.91 - 0.92 | 0.92 - 0.93 |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Mon, 27 Oct 2025
Longeveron (NASDAQ: LGVN) completes ELPIS II enrollment; HLHS trial top-line Q3 2026 - Stock Titan
Mon, 06 Oct 2025
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - Stock Titan
Thu, 04 Sep 2025
Longeveron Announces Leadership Changes Amidst CEO Departure - The Globe and Mail
Wed, 03 Sep 2025
Longeveron® Announces Key Leadership Updates - GlobeNewswire
Fri, 29 Aug 2025
Longeveron (LGVN) Secures Rights to Stem Cell Patent for Cardiac Treatment - Yahoo Finance
Wed, 13 Aug 2025
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 1.135e+007 (%) |
| Held by Institutions | 15 (%) |
| Shares Short | 1,080 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.835e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 707.9 % |
| Return on Equity (ttm) | -67.5 % |
| Qtrly Rev. Growth | 2.07e+006 % |
| Gross Profit (p.s.) | -216.67 |
| Sales Per Share | -896.8 |
| EBITDA (p.s.) | 1.08667e+007 |
| Qtrly Earnings Growth | 0.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.16 |
| Dividend | 0 |
| Forward Dividend | 1.26e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|